Repligen Corporation Q3 2025 Earnings Recap

Repligen Corporation reported strong Q3 2025 results with 18% organic growth driven by robust performance across all franchises and geographies, alongside a positive momentum in both biopharma and CDMO markets.

Key Takeaways

• Q3 organic revenue growth reached 18%, with all franchises achieving double-digit growth and analytics leading at over 50%.
• Total company orders grew sequentially for six consecutive quarters, with year-over-year order growth exceeding 20%.
• The company raised its organic growth guidance midpoint for 2025, highlighting broad strength across its portfolio.
• A partnership with Novasign aims to enhance digital twin capabilities in manufacturing processes, marking a significant step in their digitization strategy.
• Service revenue represented 5% of consolidated revenue and shows potential for future growth through expanded offerings.